Figures & data
Figure 1 Structure of CD20 and epitope targets of ofatumumab, rituximab, and obinutuzumab (GA101).
Notes: The CD20 transmembrane receptor is shown with epitopes for binding of ofatumumab, rituximab, and obinutuzumab. Adapted with permission from Klein C, Lammens A, Schafer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5(1):22–33.Citation15
Figure 2 Pharmacokinetics of obinutuzumab.
Notes: Serum concentrations of obinutuzumab based on two loading doses of 1,600 mg followed by doses of 800 mg every 2 weeks (blue line) vs continuous dosing with 400 mg every 2 weeks (yellow line), for patients with relapsed/refractory NHL. Reprinted with permission. ©2013 American Society of Clinical Oncology. all rights reserved. Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2912–2919.Citation21
Abbreviation: NHL, non-Hodgkin lymphoma.
Abbreviation: NHL, non-Hodgkin lymphoma.
Figure 3 Schematic representation of pivotal Phase III German CLL13 trial.
Notes: Patients were enrolled and randomly assigned on a 1:2:2 ratio to chlorambucil alone, rituximab plus chlorambucil, or obinutuzumab plus chlorambucil on 28-day cycles. Chlorambucil was dosed at 0.5 mg/kg on days 1 and 15. Rituximab was administered intravenously at a dose of 375 mg/m2 on day 1 of cycle 1 and 500 mg/m2 on day 1 of cycles 2–6. Obinutuzumab was administered intravenously at a dose of 1,000 mg on day 1 initially and – during subsequent amendments – over a period of 2 days, days 8 and 15 of cycle 1, and on day 1 of cycles 2–6.Citation31
Abbreviations: CLL, chronic lymphocytic leukemia; CIRS, Cumulative Illness Rating Scale.
Abbreviations: CLL, chronic lymphocytic leukemia; CIRS, Cumulative Illness Rating Scale.
